Genedata, a leading provider of advanced software solutions for drug discovery and life science research, announced release 8.0 of Genedata Expressionist® for Mass Spectrometry, which provides a single platform for the integrated analysis of metabolomics data. To explore the vast chemical space of the metabolome, researchers use a variety of mass spectrometers, including various LC-MS and GC-MS instruments. However, consolidating data from different instrument types and manufacturers can pose burdensome challenges. The new Genedata Expressionist for Mass Spectrometry addresses these challenges by combining all data types generated by diverse mass spectrometry instrument parks, and providing workflows for integrated analysis of CE-, IC-, LC- and GC-MS data. Researchers can capitalize on simultaneous processing, multivariate statistics and sophisticated pathway analyses of unified data sets to achieve a more comprehensive and holistic view of the metabolome.
“The forthcoming challenges are on the side of the poly-omics integration in big meta-metabolomics studies, and the accurate data handling of increasing numbers of samples such as in personalized medicine or global environmental/microbiome metabolomics studies,” said Prof. Dr. Schmitt-Kopplin, director of analytical biochemistry research at the Helmholtz Center Munich. Using Genedata Expressionist for Mass Spectrometry as a data analysis hub for metabolomics R&D, Prof. Dr. Schmitt-Kopplin noted, “We need algorithms that enable us to efficiently analyze several hundreds of samples in the shortest amount of time while providing high-quality results – and Genedata Expressionist enables all that and more.”
Innovative Algorithms and Interactive Visualization Drive New Insights
In recent years, Genedata Expressionist for Mass Spectrometry has found a rapidly growing user base in leading commercial organizations including pharmaceutical, agrochemical, breeding, and industrial biotechnology companies as well as academia. With interactive visualization tools, innovative peak picking algorithms and the ability to interrogate a large range of natural-substance databases, Genedata Expressionist helps to quickly identify biologically-relevant metabolites. Advanced data management capabilities keep experiment data organized and accessible.
“The ease of use, flexible automation, interactive visualizations and consistent quality of results would all be convincing enough on their own, but, it’s the scalability that really clinches it for us,” said Prof. Lothar Willmitzer, director of molecular physiology at the Max Planck Institute and co-founder of MetaSysX. “Expressionist is the only software solution that can simultaneously process the 1,000s of chromatograms we produce in our large-scale experiments.”
“The latest version of Genedata Expressionist for Mass Spectrometry underscores our commitment to meeting the specific needs of metabolomics research community,” commented Dr. Othmar Pfannes, CEO of Genedata. "Our instrument vendor-independent enterprise expertise combined with our continuous investment in innovation will ensure that our customers remain at the cutting-edge of metabolomics research.”
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US.
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.